There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zimmer Biomet Holdings (ZBH – Research Report) and Pieris Pharmaceuticals (PIRS – Research Report) with bullish sentiments.
Zimmer Biomet Holdings (ZBH)
Canaccord Genuity analyst Kyle Rose maintained a Buy rating on Zimmer Biomet Holdings today and set a price target of $185.00. The company’s shares closed last Wednesday at $147.81.
According to TipRanks.com, Rose is a 5-star analyst with an average return of 21.1% and a 57.7% success rate. Rose covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, REPRO-MED Systems, and SeaSpine Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zimmer Biomet Holdings with a $193.33 average price target, a 26.6% upside from current levels. In a report released yesterday, Northland Securities also maintained a Buy rating on the stock with a $200.00 price target.
Pieris Pharmaceuticals (PIRS)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Pieris Pharmaceuticals, with a price target of $9.00. The company’s shares closed last Wednesday at $3.54.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 25.4% and a 43.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pieris Pharmaceuticals with a $7.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.